With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
June 16, 2017. Same biologic success song, different targeted-protein verse. The ALCANZA trialpublished last week in Lancet showed improved durable (≥4 months) response rates in cutaneous T-cell lymphoma with brentuximab vedotin (a CD30 antibody-drug conjugate). This RCT enrolled 131 patients with MF or ALCL which failed prior therapy to receive brentuximab vedotin versus physician’s choice of oral MTX or bexarotene for up to 48 weeks. Those randomized to receive brentuximab vedotin had over triple the durable global response rate (56.3%) versus physician’s choice (12.5%, p<0·0001). And if you’re still confused from yesterday about what distinguishes a biologic from other chemical targeted-therapies: here’s an oldie but a goodie.